Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Matsui

Showing results (821-830 of 839) with videos related to

Pageof 84
Sort By:
Leukemia & Lymphoma|July 28, 2012
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemiaYvette L Kasamon, Robert A Brodsky, Michael J Borowitz, et al.
Leukemia Research|July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSFB Douglas Smith, Richard J Jones, Eunpi Cho, et al.
Leukemia|October 14, 2014
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDSD Inoue, J Kitaura, H Matsui, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2018
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow TransplantationYvette L Kasamon, Ephraim J Fuchs, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2017
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2015
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA FactorsJennifer A Kanakry, Christopher D Gocke, Javier Bolaños-Meade, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 2, 2019
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Rapaprotin is Activated by an Endopeptidase to Disassemble 26S ProteasomeHanjing Peng, Zufeng Guo, Wei Li Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 30, 2017
Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow TransplantationPhilip H Imus, Amanda L Blackford, Maria Bettinotti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not OutcomesShannon R McCurdy, Stephen T Muth, Hua-Ling Tsai, et al.
Pageof 84

Showing results (821-830 of 839) with videos related to

Sort By:
Pageof 84
Leukemia & Lymphoma|July 28, 2012
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemiaYvette L Kasamon, Robert A Brodsky, Michael J Borowitz, et al.
Leukemia Research|July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSFB Douglas Smith, Richard J Jones, Eunpi Cho, et al.
Leukemia|October 14, 2014
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDSD Inoue, J Kitaura, H Matsui, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2018
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow TransplantationYvette L Kasamon, Ephraim J Fuchs, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2017
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2015
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA FactorsJennifer A Kanakry, Christopher D Gocke, Javier Bolaños-Meade, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 2, 2019
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Rapaprotin is Activated by an Endopeptidase to Disassemble 26S ProteasomeHanjing Peng, Zufeng Guo, Wei Li Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 30, 2017
Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow TransplantationPhilip H Imus, Amanda L Blackford, Maria Bettinotti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not OutcomesShannon R McCurdy, Stephen T Muth, Hua-Ling Tsai, et al.
Pageof 84